Diane S Abou1, Thomas Ku, Peter M Smith-Jones. 1. Department of Radiology, Radiochemistry Service, Memorial Sloan Kettering Cancer Center, Box 16, New York, NY 10065, USA. aboud@mskcc.org
Abstract
INTRODUCTION: The present investigation focuses on the chemical and biological fate of (89)Zr in mice. Electrophoreses of (89)Zr solvated or chelated in different conditions are here presented. The biological fate of mice injected with [(89)Zr]Zr-oxalate, [(89)Zr]Zr-chloride, [(89)Zr]Zr-phosphate, [(89)Zr]Zr-desferrioxamine and [(89)Zr]Zr-citrate is studied with the biodistribution, the clearances and positron emission tomography images. A special focus is also given regarding the quality of (89)Zr bone accumulation. METHODS: Electrophoreses were carried out on chromatography paper and read by gamma counting. Then, the solutions were intravenously injected in mice, imaged at different time points and sacrificed. The bones, the epiphysis and the marrow substance were separated and evaluated with gamma counts. RESULTS: The clearances of [(89)Zr]Zr-chloride and [(89)Zr]Zr-oxalate reached 20% of injected dose (ID) after 6 days whereas [(89)Zr]Zr-phosphate was only 5% of ID. [(89)Zr]Zr-citrate and [(89)Zr]Zr-DFO were noticeably excreted after the first day postinjection (p.i.). [(89)Zr]Zr-chloride and [(89)Zr]Zr-oxalate resulted in a respective bone uptake of ∼15% ID/g and∼20% ID/g at 8 h p.i. with minor losses after 6 days. [(89)Zr]Zr-citrate bone uptake was also observed, but [(89)Zr]Zr-phosphate was absorbed in high amounts in the liver and the spleen. The marrow cells were insignificantly radioactive in comparison to the calcified tissues. CONCLUSION: Despite the complexity of Zr coordination, the electrophoretic analyses provided detailed evidences of Zr charges either as salts or as complexes. This study also shows that weakly chelated, (89)Zr is a bone seeker and has a strong affinity for phosphate.
INTRODUCTION: The present investigation focuses on the chemical and biological fate of (89)Zr in mice. Electrophoreses of (89)Zr solvated or chelated in different conditions are here presented. The biological fate of mice injected with [(89)Zr]Zr-oxalate, [(89)Zr]Zr-chloride, [(89)Zr]Zr-phosphate, [(89)Zr]Zr-desferrioxamine and [(89)Zr]Zr-citrate is studied with the biodistribution, the clearances and positron emission tomography images. A special focus is also given regarding the quality of (89)Zr bone accumulation. METHODS: Electrophoreses were carried out on chromatography paper and read by gamma counting. Then, the solutions were intravenously injected in mice, imaged at different time points and sacrificed. The bones, the epiphysis and the marrow substance were separated and evaluated with gamma counts. RESULTS: The clearances of [(89)Zr]Zr-chloride and [(89)Zr]Zr-oxalate reached 20% of injected dose (ID) after 6 days whereas [(89)Zr]Zr-phosphate was only 5% of ID. [(89)Zr]Zr-citrate and [(89)Zr]Zr-DFO were noticeably excreted after the first day postinjection (p.i.). [(89)Zr]Zr-chloride and [(89)Zr]Zr-oxalate resulted in a respective bone uptake of ∼15% ID/g and∼20% ID/g at 8 h p.i. with minor losses after 6 days. [(89)Zr]Zr-citrate bone uptake was also observed, but [(89)Zr]Zr-phosphate was absorbed in high amounts in the liver and the spleen. The marrow cells were insignificantly radioactive in comparison to the calcified tissues. CONCLUSION: Despite the complexity of Zr coordination, the electrophoretic analyses provided detailed evidences of Zr charges either as salts or as complexes. This study also shows that weakly chelated, (89)Zr is a bone seeker and has a strong affinity for phosphate.
Authors: Peter M Smith-Jones; Shankar Vallabhajosula; Vincent Navarro; Diego Bastidas; Stanley J Goldsmith; Neil H Bander Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057
Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Jason P Holland; Eloisi Caldas-Lopes; Vadim Divilov; Valerie A Longo; Tony Taldone; Danuta Zatorska; Gabriela Chiosis; Jason S Lewis Journal: PLoS One Date: 2010-01-25 Impact factor: 3.240
Authors: W E Meijs; H J Haisma; R Van der Schors; R Wijbrandts; K Van den Oever; R P Klok; H M Pinedo; J D Herscheid Journal: Nucl Med Biol Date: 1996-05 Impact factor: 2.408
Authors: Christopher G England; Emily B Ehlerding; Reinier Hernandez; Brian T Rekoske; Stephen A Graves; Haiyan Sun; Glenn Liu; Douglas G McNeel; Todd E Barnhart; Weibo Cai Journal: J Nucl Med Date: 2016-08-04 Impact factor: 10.057
Authors: Michael R Weist; Renate Starr; Brenda Aguilar; Junie Chea; Joshua K Miles; Erasmus Poku; Ethan Gerdts; Xin Yang; Saul J Priceman; Stephen J Forman; David Colcher; Christine E Brown; John E Shively Journal: J Nucl Med Date: 2018-05-04 Impact factor: 10.057
Authors: Diane S Abou; Daniel L J Thorek; Nicholas N Ramos; Martijn W H Pinkse; Hubert T Wolterbeek; Sean D Carlin; Bradley J Beattie; Jason S Lewis Journal: Pharm Res Date: 2012-12-07 Impact factor: 4.200